Impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study.

<h4>Background</h4>The aim of the present study is to evaluate the impact of glucose-lowering agents in the risk of cancer in a large type 2 diabetic population.<h4>Methods</h4>A nested case-control study was conducted within a defined cohort (275,164 type 2 diabetic patients...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rafael Simó, Oleguer Plana-Ripoll, Diana Puente, Rosa Morros, Xavier Mundet, Luz M Vilca, Cristina Hernández, Inmaculada Fuentes, Adriana Procupet, Josep M Tabernero, Concepción Violán
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2013
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/3a6c8effd09e40eea3ed7ac2fe186cc2
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3a6c8effd09e40eea3ed7ac2fe186cc2
record_format	dspace
spelling	oai:doaj.org-article:3a6c8effd09e40eea3ed7ac2fe186cc22021-11-18T08:45:16ZImpact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study.1932-620310.1371/journal.pone.0079968https://doaj.org/article/3a6c8effd09e40eea3ed7ac2fe186cc22013-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24278227/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Background</h4>The aim of the present study is to evaluate the impact of glucose-lowering agents in the risk of cancer in a large type 2 diabetic population.<h4>Methods</h4>A nested case-control study was conducted within a defined cohort (275,164 type 2 diabetic patients attending 16 Primary Health Care Centers of Barcelona). Cases (n = 1,040) comprised those subjects with any cancer diagnosed between 2008 and 2010, registered at the Cancer Registry of Hospital Vall d'Hebron (Barcelona). Three control subjects for each case (n = 3,120) were matched by age, sex, diabetes duration, and geographical area. The treatments analyzed (within 3 years prior to cancer diagnosis) were: insulin glargine, insulin detemir, human insulin, fast-acting insulin and analogues, metformin, sulfonylureas, repaglinide, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, and alpha glucosidase inhibitors. Conditional logistic regressions were used to calculate the risk of cancer associated with the use of each drug adjusted by age, BMI, dose and duration of treatment, alcohol use, smoking habit, and diabetes duration.<h4>Results</h4>No differences were observed between case and control subjects for the proportion, dose or duration of exposure to each treatment. None of the types of insulin and oral agents analyzed showed a significant increase in the risk of cancer. Moreover, no cancer risk was observed when glargine was used alone or in combination with metformin.<h4>Conclusions</h4>Our results suggest that diabetes treatment does not influence the risk of cancer associated with type 2 diabetes. Therefore, an eventual increase of cancer should not be a reason for biasing the selection of any glucose-lowering treatment in type 2 diabetic population.Rafael SimóOleguer Plana-RipollDiana PuenteRosa MorrosXavier MundetLuz M VilcaCristina HernándezInmaculada FuentesAdriana ProcupetJosep M TaberneroConcepción ViolánPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 8, Iss 11, p e79968 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Rafael Simó Oleguer Plana-Ripoll Diana Puente Rosa Morros Xavier Mundet Luz M Vilca Cristina Hernández Inmaculada Fuentes Adriana Procupet Josep M Tabernero Concepción Violán Impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study.
description	<h4>Background</h4>The aim of the present study is to evaluate the impact of glucose-lowering agents in the risk of cancer in a large type 2 diabetic population.<h4>Methods</h4>A nested case-control study was conducted within a defined cohort (275,164 type 2 diabetic patients attending 16 Primary Health Care Centers of Barcelona). Cases (n = 1,040) comprised those subjects with any cancer diagnosed between 2008 and 2010, registered at the Cancer Registry of Hospital Vall d'Hebron (Barcelona). Three control subjects for each case (n = 3,120) were matched by age, sex, diabetes duration, and geographical area. The treatments analyzed (within 3 years prior to cancer diagnosis) were: insulin glargine, insulin detemir, human insulin, fast-acting insulin and analogues, metformin, sulfonylureas, repaglinide, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, and alpha glucosidase inhibitors. Conditional logistic regressions were used to calculate the risk of cancer associated with the use of each drug adjusted by age, BMI, dose and duration of treatment, alcohol use, smoking habit, and diabetes duration.<h4>Results</h4>No differences were observed between case and control subjects for the proportion, dose or duration of exposure to each treatment. None of the types of insulin and oral agents analyzed showed a significant increase in the risk of cancer. Moreover, no cancer risk was observed when glargine was used alone or in combination with metformin.<h4>Conclusions</h4>Our results suggest that diabetes treatment does not influence the risk of cancer associated with type 2 diabetes. Therefore, an eventual increase of cancer should not be a reason for biasing the selection of any glucose-lowering treatment in type 2 diabetic population.
format	article
author	Rafael Simó Oleguer Plana-Ripoll Diana Puente Rosa Morros Xavier Mundet Luz M Vilca Cristina Hernández Inmaculada Fuentes Adriana Procupet Josep M Tabernero Concepción Violán
author_facet	Rafael Simó Oleguer Plana-Ripoll Diana Puente Rosa Morros Xavier Mundet Luz M Vilca Cristina Hernández Inmaculada Fuentes Adriana Procupet Josep M Tabernero Concepción Violán
author_sort	Rafael Simó
title	Impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study.
title_short	Impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study.
title_full	Impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study.
title_fullStr	Impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study.
title_full_unstemmed	Impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study.
title_sort	impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. the barcelona case-control study.
publisher	Public Library of Science (PLoS)
publishDate	2013
url	https://doaj.org/article/3a6c8effd09e40eea3ed7ac2fe186cc2
work_keys_str_mv	AT rafaelsimo impactofglucoseloweringagentsontheriskofcancerintype2diabeticpatientsthebarcelonacasecontrolstudy AT oleguerplanaripoll impactofglucoseloweringagentsontheriskofcancerintype2diabeticpatientsthebarcelonacasecontrolstudy AT dianapuente impactofglucoseloweringagentsontheriskofcancerintype2diabeticpatientsthebarcelonacasecontrolstudy AT rosamorros impactofglucoseloweringagentsontheriskofcancerintype2diabeticpatientsthebarcelonacasecontrolstudy AT xaviermundet impactofglucoseloweringagentsontheriskofcancerintype2diabeticpatientsthebarcelonacasecontrolstudy AT luzmvilca impactofglucoseloweringagentsontheriskofcancerintype2diabeticpatientsthebarcelonacasecontrolstudy AT cristinahernandez impactofglucoseloweringagentsontheriskofcancerintype2diabeticpatientsthebarcelonacasecontrolstudy AT inmaculadafuentes impactofglucoseloweringagentsontheriskofcancerintype2diabeticpatientsthebarcelonacasecontrolstudy AT adrianaprocupet impactofglucoseloweringagentsontheriskofcancerintype2diabeticpatientsthebarcelonacasecontrolstudy AT josepmtabernero impactofglucoseloweringagentsontheriskofcancerintype2diabeticpatientsthebarcelonacasecontrolstudy AT concepcionviolan impactofglucoseloweringagentsontheriskofcancerintype2diabeticpatientsthebarcelonacasecontrolstudy
_version_	1718421315550969856

Impact of glucose-lowering agents on the risk of cancer in type 2 diabetic patients. The Barcelona case-control study.

Ejemplares similares